All In MedTech

FDA Clearance Tracker · P110019-S115

XIENCE Alpine Everolimus Eluting Coronary Stent Systems (XIENCE Alpine EECSS), XIENCE Sierra Everolimus Eluting Coronary

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Jun 25, 2021 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Jun 25, 2021

Approved

Time to decision

179 days

Received Dec 28, 2020. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Panel Track

Device class

Class III

The decision

FDA number
P110019-S115
Device name
XIENCE Alpine Everolimus Eluting Coronary Stent Systems (XIENCE Alpine EECSS), XIENCE Sierra Everolimus Eluting Coronary
Applicant location
Santa Clara, CA
Received
Dec 28, 2020
Decided
Jun 25, 2021
Decision
Approved
Supplement type
Panel Track
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P110019

Device type

Device class
Class III

Every decision under product code NIQ

FDA's approval statement

As written in FDA's record.

Approval for the XIENCE Alpine Everolimus Eluting Coronary Stent Systems (XIENCE Alpine EECSS), XIENCE Sierra Everolimus Eluting Coronary Stent Systems (XIENCE Sierra EECSS), and the XIENCE Skypoint Everolimus Eluting Coronary Stent System (XIENCE Skypoint EECSS).The XIENCE [Alpine / Sierra / Skypoint] stent system is indicated for improving coronary artery luminal diameter in patients, including those at high risk for bleeding and those with diabetes mellitus, with symptomatic heart disease due to de novo native coronary artery lesions (length <= 32 mm) with reference vessel diameters of >= 2.25 mm to <= 4.25 mm. In addition, the XIENCE [Alpine / Sierra / Skypoint] stent system is indicated for treating de novo chronic total coronary occlusions.

Source documents

Other decisions for Abbott Vascular

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.